I thank the Reviewers for their suggestions. In blue my answers.

Reviewer 1

Author transmit an enthusiastic support of precision medicine in CF disease management on the robust genomic basis that comprises technologies to stratify the patient population and to alleviate the burden of ADRs. In this context, drug treatment selection and prediction of its outcomes are important for optimal management of CF patient

Reviewer 2

The following changes are proposed to make easier the reading of the review:

Break down the introduction section into three or four paragraphs.

Done.

In the introduction include a figure indicating the structure of the CFTR gene.

Done. The permission to reproduce the image was requested.

The second paragraph of the “Genotype-Phenotype Relationship” section is very long. Break it down in more than one paragraph and include a figure indicating the classification of the CFTR mutations.

Done. I would prefer to add the classification of CFTR mutations in the new Table 1 (instead of a figure).

In the “Next Generation Sequencing” section include a table comparing the currently used with the NGS approaches indicating their advantages/disadvantages.

Done. The new Table 2 was added.

It would be easier for the reader to capture the take home message of the material included in the “Personalized Therapy” section if the content of this section was organized in a Table.

Done. I added the approaches for the personalized therapy to the new Table 1.

Include a “Future Directions” section in which some of the material included in the NGS section could be transferred.

Done. We added future directions in a pooled section “Conclusions and future directions”.